Efficacy and safety of intravenous XXXX for @entity4710 .

@entity1 @entity4710 @entity551 @entity5894
In a double-blind, placebo-controlled, parallel trial of intravenous @entity5894 in the treatment of sustained @entity4710 ( @entity4710 ), 29 @entity1 (20 @entity1 , 9 @entity1 ) were studied. Mean age was 55 years and all @entity1 were required to have well-documented @entity4710 with a ventricular rate greater than or equal to 120/min that was sustained for at least 30 minutes. @entity1 received sequential doses of 0.01, 0.02 and 0.04 mg/kg of @entity5894 or placebo at 10 minute intervals. The maximum total dosage of @entity5894 was 10 mg. Measurements taken during 10 minute monitoring periods after each administration included heart rate, @entity551 . A positive response was defined as a greater than or equal to 20% decrease in heart rate, heart rate less than or equal to 100 beats/min or conversion to normal sinus rhythm. Eleven (79%) of @entity1 given @entity5894 and 3 (20%) of placebo-treated @entity1 demonstrated a positive response. Of the 11 responders to @entity5894 , 9 @entity1 responded after the first dose, one after the second dose and one after the third dose. Significant (p less than 0.001) mean reductions in heart rate and ventricular rate were observed with @entity5894 , but not with placebo. Five (36%) of the @entity1 given @entity5894 and only 2 (14%) of the @entity1 who received placebo were converted to normal sinus rhythm. Adverse effects were limited to 1 episode of asymptomatic @entity551 and 1 episode of wheezing with @entity5894 and 1 episode of asymptomatic @entity551 with placebo. @entity5894 is effective in controlling ventricular response in @entity1 with sustained @entity4710 .(ABSTRACT TRUNCATED AT 250 WORDS)
